Početna stranicaJAZZ • NASDAQ
add
Jazz Pharmaceuticals PLC
103,38 $
Poslije radnog vremena:(0,00 %)0,00
103,38 $
Zatvoreno: 22. tra, 16:29:17 GMT -4 · USD · NASDAQ · Odricanje od odgovornosti
Preth. zaklj. cijena
100,34 $
Dnevni raspon
101,22 $ - 103,86 $
Godišnji raspon
95,49 $ - 148,06 $
Tržišna kapitalizacija
6,28 mlr. USD
Prosječna količina
1,40 mil.
P/E omjer
11,95
Prinos dividende
-
Glavno tržište vrijednosnica
NASDAQ
U vijestima
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
| (USD) | pro 2024.info | Godišnja promjena |
|---|---|---|
Prihod | 1,09 mlr. | 7,53 % |
Operativni troškovi | 768,69 mil. | 9,42 % |
Neto dohodak | 191,12 mil. | 102,98 % |
Neto profitabilnost | 17,56 | 88,82 % |
Zarada po dionici | 6,60 | 31,47 % |
EBITDA | 396,98 mil. | 0,82 % |
Efektivna porezna stopa | −43,48 % | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
| (USD) | pro 2024.info | Godišnja promjena |
|---|---|---|
Gotovinska i kratkoročna ulaganja | 2,99 mlr. | 83,66 % |
Ukupna imovina | 12,01 mlr. | 5,43 % |
Ukupne obveze | 7,92 mlr. | 3,42 % |
Ukupni kapital | 4,09 mlr. | — |
Dionice u optjecaju | 60,73 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | 1,49 | — |
Povrat imovine | 4,71 % | — |
Povrat kapitala | 5,54 % | — |
Tok novca
Neto promjena novca
| (USD) | pro 2024.info | Godišnja promjena |
|---|---|---|
Neto dohodak | 191,12 mil. | 102,98 % |
Gotovina od poslovanja | 398,58 mil. | 138,19 % |
Gotovina iz ulaganja | −193,29 mil. | −289,87 % |
Gotovina iz financiranja | −8,28 mil. | 91,75 % |
Neto promjena novca | 194,73 mil. | 14,13 % |
Slobodan tok novca | 466,32 mil. | 470,30 % |
Više
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States. One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.
The company is also a member of the Pharmaceutical Research and Manufacturers of America. Wikipedia
Glavni izvršni direktor
Osnovano
2003
Web-lokacija
Zaposlenici
2.800
